IN THE CLAIMS

The following listing of claims will replace all prior versions and listings of claims in the present application.

1–8 (cancelled).

9 (withdrawn). A therapeutic combination comprising (a) rotigotine or a metabolite, prodrug or physiologically acceptable salt thereof, and (b) one or more additional active ingredients comprising one or more antidepressants, antipsychotics, sedatives, anxiolytics and/or anti-migraine agents.

10 (previously presented). A method for treating depression in a mammal, comprising administering a therapeutically effective quantity of rotigotine or a metabolite, prodrug or physiologically acceptable salt thereof, to said mammal.

11 (previously presented). The method of claim 10, wherein the mammal is human.

12 (previously presented). The method of Claim 11, wherein the depression is an endogenous depression.

13 (previously presented). The method of Claim 12, wherein the endogenous depression is a unipolar depression (major depression) or a depressive episode of a manic-depressive disorder.

14 (previously presented). The method of Claim 32, wherein the somatogenic depression is an organic depression not associated with Parkinson's disease.

15 (previously presented). The method of Claim 32, wherein the somatogenic depression is an organic depression associated with Parkinson's disease.

16 (previously presented). The method of Claim 15, wherein co-medication with another antidepressant is absent.

17 (currently amended). The method of Claim 11, wherein the rotigotine ~~**or metabolite, prodrug or salt thereof**~~ is administered parenterally, transdermally or mucosally.

18 (currently amended). The method of Claim 11, wherein the rotigotine ~~**or metabolite, prodrug or salt thereof**~~ is administered in a dosage of 0.5 to about 50 mg per day.

19 (currently amended). The method of Claim 11, wherein the rotigotine ~~**or metabolite, prodrug or salt thereof**~~ is administered in a dosage of 0.5 to 10 mg per day.

20 (currently amended). The method of Claim 11, wherein the rotigotine ~~**or metabolite, prodrug or salt thereof**~~ is administered in a dosage of 0.5 to 5 mg per day.

21 (previously presented). The method of claim 10, wherein the rotigotine is administered as a prodrug thereof.

22 (previously presented). The method of Claim 21, wherein the prodrug is an ester, carbamate, carbonate, ketal, acetate, phosphate, phosphonate, sulfate or sulfonate.

23 (previously presented). The method of Claim 10, wherein the rotigotine is administered transdermally as rotigotine free base or hydrochloride salt.

24 (previously presented). The method of Claim 23, wherein the rotigotine is formulated as an ointment, paste, spray, film, plaster or iontophoretic device for transdermal administration.

25 (previously presented). The method of Claim 23, wherein the rotigotine is formulated as a plaster having the rotigotine in a matrix comprising an adhesive polymer.

26 (previously presented). The method of Claim 23, wherein a substantially constant plasma level of rotigotine is established.

27 (previously presented). The method of Claim 10, further comprising administering to the mammal one or more antidepressants.

28 (withdrawn). The combination of Claim 9, wherein the one or more additional active ingredients comprise one or more antidepressants comprising one or more selective serotonin reuptake inhibitors, mixed serotonin and noradrenalin reuptake inhibitors, selective noradrenaline reuptake inhibitors, monoamine oxidase inhibitors, alpha2 receptor modulators, serotonin receptor modulators, adenosine antagonists, sigma-opioid receptor ligands, NK antagonists, melatonin antagonists and/or modulators of the hypothalamus-hypophysis-adrenal axis.

29 (currently amended). The method of Claim 10, wherein the rotigotine ~~**or metabolite, prodrug or salt thereof**~~ is administered in monotherapy.

30 (currently amended). The method of Claim 10, wherein the quantity of rotigotine ~~**or metabolite, prodrug or salt thereof**~~ is effective for alleviation of symptoms of Parkinson's disease and for treatment of depression.

31 (currently amended). The method of Claim 30, wherein the rotigotine ~~**or metabolite, prodrug or salt thereof**~~ is administered in monotherapy.

32 (previously presented). The method of Claim 11, wherein the depression is a somatogenic depression.

33 (previously presented). The method of Claim 14, wherein the organic depression is associated with brain tumor, migraine, epilepsy, brain paralysis, arteriosclerosis of the brain, brain trauma, meningitis, stroke, Parkinson Plus syndrome, dementia and/or cerebrovascular disease.

34 (previously presented). The method of Claim 14, wherein the organic depression is associated with Alzheimer's disease.

35 (previously presented). The method of Claim 32, wherein the somatogenic depression is a symptomatic depression.

36 (previously presented). The method of Claim 35, wherein the symptomatic depression is associated with circulatory illness, hypothyroidism, hormone disorder, infectious disease, cancer and/or liver disease.

37 (previously presented). The method of Claim 32 wherein the somatogenic depression is a pharmacogenic depression.

38 (previously presented). The method of Claim 37, wherein the pharmacogenic depression is associated with alcohol, medication and/or drug misuse.

39 (previously presented). The method of Claim 11, wherein the depression is a psychogenic depression.

40 (previously presented). The method of Claim 39, wherein the psychogenic depression comprises at least one of exhaustion depression, neurotic depression and reactive depression as a result of current conflicts or events.

41 (previously presented). The method of Claim 11, wherein the depression occurs in particular circumstances, comprising at least one of postpartum depression, old-age depression, childhood depression, seasonal depression and pubertal depression.

42 (previously presented). The method of Claim 10, wherein the depression is associated with an affective disorder.

43 (previously presented). The method of Claim 42, wherein the affective disorder comprises a recurrent depressive disorder and/or depressive phases in bipolar affective disorder.

44 (previously presented). The method of Claim 11, wherein the depression manifests as depressive symptoms accompanying at least one anxiety disorder, adjustment disorder and/or organic brain disease.

45 (currently amended). The method of Claim 11, wherein the rotigotine ~~or metabolite, prodrug or salt thereof~~ is administered in a dosage of 0.1 to about 50 mg per day.

46 (currently amended). The method of Claim 11, wherein the rotigotine ~~or metabolite, prodrug or salt thereof~~ is administered in a dosage of 0.2 to 40 mg per day.

47 (currently amended). The method of Claim 11, wherein the rotigotine ~~or metabolite, prodrug or salt thereof~~ is administered in a dosage of 0.4 to 20 mg per day.

48 (previously presented). The method of Claim 11, wherein the rotigotine or metabolite, prodrug or salt thereof is administered in an amount effective to obtain a plasma rotigotine concentration of 0.05 to 20 ng/ml.

49 (previously presented). The method of Claim 11, wherein the rotigotine or metabolite, prodrug or salt thereof is administered in an amount effective to obtain a plasma rotigotine concentration of 0.1 to 10 ng/ml.

50 (previously presented). The method of Claim 11, wherein the rotigotine or metabolite, prodrug or salt thereof is administered in an amount effective to obtain a plasma rotigotine concentration of 0.2 to 5 ng/ml.

51 (previously presented). The method of Claim 11, wherein the rotigotine or metabolite, prodrug or salt thereof is administered in an amount effective to obtain a plasma rotigotine concentration of 0.1 to 0.5 ng/ml.

52 (previously presented). The method of Claim 21, wherein the prodrug is administered in an amount effective to obtain a plasma rotigotine concentration of 0.05 to 20 ng/ml.

53 (previously presented). The method of Claim 52, wherein the prodrug is administered in an amount effective to obtain a plasma rotigotine concentration of 0.1 to 10 ng/ml.

54 (previously presented). The method of Claim 52, wherein the prodrug is administered in an amount effective to obtain a plasma rotigotine concentration of 0.2 to 5 ng/ml.

55 (previously presented). The method of Claim 52, wherein the prodrug is administered in an amount effective to obtain a plasma rotigotine concentration of 0.1 to 0.5 ng/ml.

56 (previously presented). The method of Claim 26, wherein the rotigotine is administered in an amount effective to obtain a plasma rotigotine concentration of 0.05 to 20 ng/ml.

57 (previously presented). The method of Claim 26, wherein the rotigotine is administered in an amount effective to obtain a plasma rotigotine concentration of 0.1 to 10 ng/ml.

58 (previously presented). The method of Claim 26, wherein the rotigotine is administered in an amount effective to obtain a plasma rotigotine concentration of 0.2 to 5 ng/ml.

59 (previously presented). The method of Claim 26, wherein the rotigotine is administered in an amount effective to obtain a plasma rotigotine concentration of 0.1 to 0.5 ng/ml.

60 (previously presented). The method of Claim 27, wherein the one or more antidepressants comprise one or more serotonin reuptake inhibitors, mixed serotonin and noradrenalin reuptake inhibitors, selective noradrenaline reuptake inhibitors, monoamine oxidase inhibitors, alpha2 receptor modulators, serotonin receptor modulators, adenosine antagonists, sigma-opioid receptor ligands, NK antagonists, melatonin antagonists and/or modulators of the hypothalamus-hypophysis-adrenal axis.

61 (previously presented). The method of Claim 60, wherein the one or more anti-depressants comprise at least one of sertaline, citalopram, partoxetine, fluoxetine, venlaxafine, milnacipram, mirtazapine, amitryptiline, imipramine, reboxetine, tranylcypramine, clorgyline, and/or nefazodone.

62 (previously presented) . The method of Claim 10, further comprising administering to the mammal one or more antipsychotics.

63 (previously presented). The method of Claim 62, wherein the one or more antipsychotics comprise at least one of promethazine, fluphenazine, perphenazine, levomepromazine, thioridazine, perazine, promazine, chlorprothixene, zuclopenthixol, prothipendyl, flupentixol, zotepine, benperidol, pipamperon, melperon, haloperidol, bromperidol, sulpiride, clozapine, pimozide, risperidone, quetiapine, amisulpride and/or olanzapine.

64 (previously presented). The method of Claim 10, further comprising administering to the mammal one or more sedatives.

65 (previously presented). The method of Claim 64, wherein the one or more sedatives comprise at least one of diphenhydramine, doxylamine succinate, nitrazepam, midazolam, lormetazepam, flunitrazepam, flurazepam, oxazepam, bromazepam, triazolam, brotizolam, temazepam, chloral hydrate, zopiclone, zolpidem, tryptophan and/or zaleplon.

66 (previously presented). The method of Claim 10, further comprising administering to the mammal one or more anxiolytics.

67 (previously presented). The method of Claim 66, wherein the one or more anxiolytics comprise at least one of fluspirilene, thioridazine, oxazepam, alprazolam, bromazepam, lorazepam, prazepam, diazepam, clobazam, medazepam, chlordiazepoxide, dipotassium chlorazepate, nordazepam, meprobamate, buspirone, kavain and/or hydroxyzine.

68 (previously presented). The method of Claim 10, further comprising administering to the mammal one or more anti-migraine agents.

69 (previously presented). The method of Claim 68, wherein the one or more anti-migraine agents comprise at least one of almotriptan, zolmitriptan, acetylsalicylic acid, ergotamine, dihydroergotamine, methysergide, iprazochrome, ibuprofen, sumatriptan, rizatriptan, naratriptan and/or paracetamol.

70 (previously presented). The method of Claim 10, further comprising administering to the mammal at least one additional active ingredient comprising one or more antidepressants, antipsychotics, sedatives, anxiolytics and/or anti-migraine agents, wherein the rotigotine or metabolite, prodrug or salt thereof and the at least one additional active ingredient are provided in separate dosage forms for administration by the same or different routes at the same or different times.

71 (previously presented). The method of Claim 10, further comprising administering to the mammal at least one additional active ingredient comprising one or more antidepressants, antipsychotics, sedatives, anxiolytics and/or anti-migraine agents, wherein the rotigotine or metabolite, prodrug or salt thereof and the at least one additional active ingredient are administered in a single dosage form.

72 (withdrawn). The combination of Claim 28, wherein the one ore more antidepressants comprise at least one of sertaline, citalopram, partoxetine, fluoxetine, venlaxafine, milnacipram, mirtazapine, amitryptiline, imipramine, reboxetine, tranylcypramine, clorgyline, and/or nefazodone.

73 (withdrawn). The combination of Claim 9, wherein the one or more additional active ingredients comprise one or more antipsychotics.

74 (withdrawn). The combination of Claim 73, wherein the one or more antipsychotics comprise at least one of promethazine, fluphenazine, perphenazine, levomepromazine, thioridazine, perazine, promazine, chlorprothixene, zuclopenthixol, prothipendyl, flupentixol, zotepine, benperidol, pipamperon, melperon, haloperidol, bromperidol, sulpiride, clozapine, pimozide, risperidone, quetiapine, amisulpride and/or olanzapine.

75 (withdrawn). The combination of Claim 9, wherein the at least one or more additional active ingredients comprise one or more sedatives.

76 (withdrawn). The combination of Claim 75, wherein the one or more sedatives comprise at least one of diphenhydramine, doxylamine succinate, nitrazepam, midazolam, lormetazepam, flunitrazepam, flurazepam, oxazepam, bromazepam, triazolam, brotizolam, temazepam, chloral hydrate, zopiclone, zolpidem, tryptophan and/or zaleplon.

77 (withdrawn). The combination of Claim 9, wherein the one or more additional active ingredients comprise one or more anxiolytics.

78 (withdrawn). The combination of Claim 77, wherein the one or more anxiolytics comprise at least one of fluspirilene, thioridazine, oxazepam, alprazolam, bromazepam, lorazepam, prazepam, diazepam, clobazam, medazepam, chlordiazepoxide, dipotassium chlorazepate, nordazepam, meprobamate, buspirone, kavain and/or hydroxyzine.

79 (withdrawn). The combination of Claim 9, wherein the one or more additional active ingredients comprise one or more anti-migraine agents.

80 (withdrawn). The combination of Claim 79, wherein the one or more anti-migraine agents comprise at least one of almotriptan, zolmitriptan, acetylsalicylic acid, ergotamine,

dihydroergotamine, methysergide, iprazochrome, ibuprofen, sumatriptan, rizatriptan, naratriptan and/or paracetamol.

81 (withdrawn). The combination of Claim 9, wherein the rotigotine or metabolite, prodrug or salt thereof and the one or more additional active ingredients are present in separate dosage forms adapted for administration by the same or different routes at the same or different times.

82 (withdrawn). The combination of Claim 9, wherein the rotigotine or metabolite, prodrug or salt thereof and the one or more additional active ingredients are present in a single dosage form.